Antisoma scouts for new therapies to add to pipeline

Antisoma is sending out signals that it's looking for new acquisitions to add to its pipeline. "With a strong balance sheet, we are well placed to invest in and add value to our current pipeline and to add further promising drugs to our portfolio when opportunities arise," Antisoma Chairman Barry Price told The Guardian. The UK biotech has been making significant headway with ASA404, which has been in trials as an anti-cancer therapy. Novartis partnered up on the program last April in a deal valued at around $900 million.

- check out the report in The Guardian

Suggested Articles

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.